Progressive chronic calvarial osteomyelitis in rhino-orbital mucormycosis associated with COVID-19.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Informa Healthcare Country of Publication: England NLM ID: 8301221 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-5108 (Electronic) Linking ISSN: 01676830 NLM ISO Abbreviation: Orbit Subsets: MEDLINE
    • Publication Information:
      Publication: London : Informa Healthcare
      Original Publication: Amsterdam : Aeolus Press, [1982-
    • Subject Terms:
      Mucormycosis*/diagnostic imaging ; Mucormycosis*/therapy ; Orbital Diseases*/diagnostic imaging ; Orbital Diseases*/therapy ; COVID-19* ; Eye Diseases*/drug therapy ; Osteomyelitis*/diagnostic imaging ; Osteomyelitis*/therapy; Humans ; Antifungal Agents/therapeutic use
    • Abstract:
      We describe two cases of extensive indolent calvarial osteomyelitis after rhino-orbital-mucormycosis in diabetic patients previously diagnosed with COVID-19. Both patients presented with acute rhino-orbital symptoms about one month after being diagnosed with COVID-19. Treatment with intravenous liposomal Amphotericin B and prompt radical surgical debridement was instituted, but calvarial osteomyelitis ensued and persisted chronically despite maintenance of antifungal therapy and partial debridement of necrotic calvarial bone. The patients were discharged to continue antifungal therapy on a day-hospital regime. After more than 8 months of treatment, they remain with radiological signs of osteomyelitis but with no symptoms or intracranial extension of the infection. Calvarial indolent osteomyelitis secondary to mucormycosis is extremely rare, and little is known regarding its treatment. We believe it can be controlled with medical treatment and partial bony debridement although more studies are necessary to better define therapy.
    • Contributed Indexing:
      Keywords: COVID-19; Calvarial osteomyelitis; indolent mucormycosis; craniofacial osteomyelitis; mucormycosis
    • Accession Number:
      0 (Antifungal Agents)
    • Publication Date:
      Date Created: 20220601 Date Completed: 20240129 Latest Revision: 20240129
    • Publication Date:
      20240129
    • Accession Number:
      10.1080/01676830.2022.2080233
    • Accession Number:
      35642653